Glioblastoma Multiforme
Conditions
Brief summary
This is a phase 1 study investigating the re-purposing of chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed glioblastoma multiforme.
Detailed description
The purpose of the study is to determine the safety and acute toxicity of chlorpromazine (CPZ) when administered throughout the standard treatment protocol for glioblastoma multiforme, as well as determine progression free survival. Chlorpromazine (25 mg daily for the first 3 patients then dose escalate to 50 mg if no DLT) will be added to a standard of care regimen which includes radiation and adjuvant Temozolomide. Chlorpromazine treatment will continue for up to 6 cycles or until criteria for removal is met. Temozolomide is administered following standard practice adopted at the University of Iowa Hospitals and Clinics (UIHC). Subject will have several MRI scans for disease assessment throughout the treatment. There will be 3 phases of treatment for each patient: Concomitant Chlorpromazine- Start 7 days prior to day 1 of concurrent Temozolomide and radiation. Will continue with Chlorpromazine through radiation therapy (temozolomide will cease after 49 days) Interim Phase- When radiation has ended, subject will take Chlorpromazine for 28 days- no Temozolomide Adjuvant phase- subject resumes Temozolomide per standard practice, and continues to take Chlorpromazine through 6 cycles of Temozolomide.
Interventions
DRUGChlorpromazine
Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start. Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide. Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide.
DRUGTemozolomide
Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference. Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle.
RADIATIONRadiation Therapy
Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
Sponsors
Mohammed Milhem
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have newly diagnosed (i.e., within 5 weeks from recent surgery), histologically or cytologically or molecularly confirmed glioblastoma, gliosarcoma, or diffuse midline glioma. * Diagnosis must be made by surgical biopsy or excision. * Therapy must begin ≤ 5 weeks after most recent surgery. * Age ≥ 18 years * ECOG performance status 0-2 (Karnofsky \> 50%, see Appendix B). * A complete blood count and differential must be obtained within 21 days prior to radiation fraction 1, with adequate bone marrow functions as defined below: * Absolute neutrophil count (ANC) ≥ 1500 cells per mm\^3 * Platelets ≥ 100,000 per mm\^3 * Hemoglobin ≥ 8 g/dL * Plasma blood chemistries within 21 days of radiation fraction 1, as defined below: * Creatinine ≤ 2.0 mg/dL * Total bilirubin ≤ 1.5 mg/dL * ALT ≤ 3 times the institutional upper limit of normal * AST ≤ 3 times the institutional upper limit of normal * Patient or patient's legally authorized representative's ability to understand and willingness to sign a written informed consent document.
Exclusion criteria
* Recurrent high-grade glioma. * Significant abnormalities on ECG at screening. QTcF \> 450 msec for males or \> 470 msec for females at screening. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or chlorpromazine. * Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis, Parkinson's disease, history of myasthenia gravis, or dementia. * Patients with prior malignancies of the same or different tumor type and patients with concurrent malignancies of the same or different tumor type whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational drug. * Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma * Prior radiation therapy to the head or neck, which would result in overlap of radiation therapy fields. * Patients may not be receiving any other investigational agents. Use of tumor treating fields (TTF) in adjuvant phase is permitted as per standard of care. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypoparathyroidism, or psychiatric illness/social situations that would limit compliance with study requirements. Uncontrolled seizures despite being on maximal anti-seizure therapy. * Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a Class D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide, breastfeeding should be discontinued if the mother is treated with temozolomide.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and acute toxicity of chlorpromazine (CPZ) when administered throughout the standard treatment for glioblastoma multiforme (GBM) will be graded per NCI's Common Terminology Criteria for Adverse Events v 5.0 (CTCAE v5.0) | First treatment through 30 days post last dose of study drug | The incidence of treatment-emergent adverse events will be summarized by system organ class and/or preferred term, type of adverse event, and severity (based on NCI CTCAE v5.0 grades) |
| Recommended phase II dose of chlorpromazine in combination with the standard treatment protocol for glioblastoma | 4 weeks | The study will utilize a 3+3 design, and up to 6 patients will be treated at each dose level. The recommended Phase II dose will be defined as the highest dose level for which at most 1 of 6 patients experience a dose limiting toxicity (DLT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival of patients with newly diagnosed GBM treated with CPZ and standard chemoradiation 6 months from the date of surgery | 2 years | Time from diagnosis to documented disease progression or death due to any cause. |
| 2-year overall survival of patients with newly diagnosed GBM treated with CPZ and standard chemoradiation 6 months from the date of surgery | 2 years | Time from diagnosis up to 2 years post completion of treatment |
Countries
United States
Outcome results
None listed